SCM
SGMT icon

Sterling Capital Management’s Sagimet Biosciences SGMT Stock Holding History

Sterling Capital Management’s Portfolio SGMT Stock Details SGMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.24K Buy
+419
New +$2.85K ﹤0.01% 2833

Other funds holding SGMT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

Sterling Capital Management's SGMT Position: Q2 2026 in Review

Sterling Capital Management opened a new position in Sagimet Biosciences (SGMT) in Q2 2026: 419 shares worth $3.24K. The stake represents ﹤0.01% of the portfolio and ranks #2833 among its holdings.

122 funds tracked by Wall St. Rank hold SGMT as of Q2 2026.

  • Sterling Capital Management held 419 shares of Sagimet Biosciences worth $3.24K as of Q2 2026.
  • Sagimet Biosciences was a new Sterling Capital Management position in Q2 2026.
  • Sagimet Biosciences made up ﹤0.01% of Sterling Capital Management's portfolio in Q2 2026, its #2833 holding.
  • 122 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.